Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Breast 1

Conditions

Lung Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 24Nivolumab 19atezolizumab 9Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7durvalumab 5Ipilimumab 5fludarabine 4Trastuzumab 4cemiplimab 3cabozantinib 3avelumab 3Sunitinib 3Biopsy 3ulixertinib 2toripalimab 2tislelizumab 2spartalizumab 2sargramostim 2relatlimab 2palbociclib 2lenvatinib 2epacadostat 2enzalutamide 2cyclopropapyrroloindole 2copanlisib 2budigalimab 2aldesleukin 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × devimistat × Thoracic × Clear all
NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Cornerstone Pharmaceuticals

Phase 2 Terminated
7 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡